Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1104 • 2019 ACR/ARP Annual Meeting
Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study
Elizabeth Arkema¹, Marios Rossides ¹, Christopher Sjöwall ², Elisabet Svenungsson ³ and Julia Simard ⁴, ¹Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, ³Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Previous studies examining the relative risk (RR) associated with having a first degree relative (FDR) with systemic lupus erythematosus (SLE) were small and few…
Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Hironari Hanaoka¹, Jun Kikuchi ², Shuntaro Saito ¹, Hiroshi Takei ³, Kazuoto Hiramoto ¹, Tatsuhiro Oshige ¹, Noriyasu Seki ⁴, Hideto Tsujimoto ⁴, Yuko Kaneko ¹ and Tsutomu Takeuchi ⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Keio Universitiy School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Mitsubishi Tanabe Pharma Corporation Sohyaku, Tokyo, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…
Abstract Number: 1610 • 2019 ACR/ARP Annual Meeting
Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index
Alexandra Legge¹, Susan Kirkland ¹, Kenneth Rockwood ¹, Pantelis Andreou ¹, Sang-Cheol Bae ², Caroline Gordon ³, Juanita Romero-Diaz ⁴, Jorge Sanchez-Guerrero ⁵, Daniel J Wallace ⁶, Sasha Bernatsky ⁷, Ann E Clarke ⁸, Joan Merrill ⁹, Ellen M Ginzler ¹⁰, Paul Fortin ¹¹, Dafna Gladman ¹², Murray Urowitz ¹³, Ian Bruce ¹⁴, David A Isenberg ¹⁵, Anisur Rahman ¹⁶, Graciela Alarcón ¹⁷, Michelle Petri ¹⁸, Munther A Khamashta ¹⁹, MA Dooley ²⁰, Rosalind Ramsey-Goldman ²¹, Susan Manzi ²², Kristjan Steinsson ²³, Asad A Zoma ²⁴, Cynthia Aranow ²⁵, Meggan Mackay ²⁶, Guillermo Ruiz-Irastorza ²⁷, S Sam Lim ²⁸, Murat Inanc ²⁹, Ronald F Van Vollenhoven ³⁰, Andreas Jönsen ³¹, Ola Nived ³¹, Manuel Ramos-Casals ³², Diane Kamen ³³, Kenneth C Kalunian ³⁴, Soren Jacobsen ³⁵, Christine Peschken ³⁶, Anca Askanase ³⁷ and John G Hanly ¹, ¹Dalhousie University, Halifax, NS, Canada, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³University of Birmingham, Birmingham, United Kingdom, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁵Toronto Western Hospital, Toronto, ON, Canada, ⁶Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁷Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Oklahoma Medical Research Foundation, Oklahoma City, ¹⁰State University of New York Downstate Medical Center, Brooklyn, NY, ¹¹Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹²University of Toronto, Toronto, ON, Canada, ¹³University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁵Centre for Rheumatology, London, United Kingdom, ¹⁶University College London, London, United Kingdom, ¹⁷University of Alabama at Birmingham, Birmingham, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹King's College London School of Medicine, London, United Kingdom, ²⁰UnC Kidney Centre, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Pittsburg, PA, ²³Landspitali, University Hospital, Reykjavik, Iceland, ²⁴University of Glasgow, East Kilbride, United Kingdom, ²⁵Feinstein Institute for Medical Research, Manhasset, NY, ²⁶Feinstein Institute for Medical Research, New York, ²⁷Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁰Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³¹Lund University, Lund, Sweden, ³²Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ³³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ³⁴UC San Diego School of Medicine, LaJolla, CA, ³⁵Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁶University of Manitoba, Winnipeg, Canada, ³⁷Columbia University Medical Center, New York, NY
Background/Purpose: We previously constructed a frailty index (FI) as a measure of susceptibility to adverse outcomes among patients with systemic lupus erythematosus (SLE). In this…
Abstract Number: 1824 • 2019 ACR/ARP Annual Meeting
Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Sarah Patterson¹, Laura Trupin ¹, Cristina Lanata ¹, Louise Murphy ², Wendy Hartogenesis ¹, Maria Dall'Era ¹, Jinoos Yazdany ³ and Patricia Katz ¹, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A new posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the division of symptomatology into two groups: type 1 manifestations represent…
Abstract Number: 2032 • 2019 ACR/ARP Annual Meeting
Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation
Goh Murayama¹, Asako Chiba ², Ayako Makiyama ³, Taiga Kuga ⁴, Ken Yamaji ⁴, Naoto Tamura ⁴ and Sachiko Miyake ², ¹Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Interferona (IFNa) is increased and plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes…
Abstract Number: 2517 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS
Hakan Babaoglu¹, Jessica Li ², Daniel Goldman ³, Laurence Magder ⁴ and Michelle Petri ², ¹Gazi University School of Medicine, Ankara, Turkey, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a potential treat to target goal in systemic lupus erythematosus (SLE), has been found to correlate with…
Abstract Number: 2552 • 2019 ACR/ARP Annual Meeting
Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Sarah Gilman ¹, Deborah Levesque ², Carol Cummins ³, Daniel Wallace ⁴, Victoria Werth ⁵ and Patricia Davidson⁶, ¹Wayfinder Health Strategies, Washington, DC, ²Pro-Change Behavior Systems, Providence, RI, ³Pro-Change Behavior Systems, Inc.,, Providence, ⁴Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Lupus Foundation of America, Washington, DC
Background/Purpose: The Lupus Foundation of America is in Year 4 of a 6-year cooperative agreement with the Centers for Disease Control and Prevention to develop…
Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting
Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation
Celline C. Almeida-Brasil ¹, Evelyne Vinet ², Christian Pineau ² and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…
Abstract Number: 101 • 2018 ACR/ARHP Annual Meeting
Regulation of Monocyte Function By Epstein Barr Virus Interleukin-10 (vIL10) in Systemic Lupus Erythematosus
Neelakshi R. Jog¹, Eliza Chakravarty¹, Joel M. Guthridge¹ and Judith A. James^2,3, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by periods of elevated and suppressed disease activity. Epstein Barr Virus (EBV) has been…
Abstract Number: 738 • 2018 ACR/ARHP Annual Meeting
Two Clinical Phenotypes of Chinese SLE-PAH Patients
Fangfang Sun¹, Wanlong Wu², Li Guo¹, Zhiwei Chen¹, Xiaodong Wang¹, Ting Li¹ and Shuang Ye¹, ¹Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China, ²Department of Rheumatology, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic lupus erythematosus (SLE), which is the most common underlying disease of CTD associated PAH.…
Abstract Number: 970 • 2018 ACR/ARHP Annual Meeting
Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Daniel J. Wallace¹, Richard Furie², Yoshiya Tanaka³, Kenneth C. Kalunian⁴, Marta Mosca⁵, Michelle Petri⁶, Thomas Dorner⁷, Mario H. Cardiel⁸, Ian N. Bruce⁹, Elisa Gomez¹⁰, Amy M. DeLozier¹⁰, Jonathan Janes¹⁰, Matthew D Linnik¹⁰, Stephanie de Bono¹⁰, Maria E. Silk¹⁰ and Robert W. Hoffman¹⁰, ¹Cedars-Sinai Medical Center/David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of California at San Diego School of Medicine, La Jolla, CA, ⁵University of Pisa, Pisa, Italy, ⁶Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Charité Universitätmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ⁸Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁰Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (Bari), an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, has been approved for the treatment of RA in the Europe and…
Abstract Number: 1671 • 2018 ACR/ARHP Annual Meeting
Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
Cynthia Aranow¹, Anca Askanase², Molla Huq³, Shereen Oon⁴, Alicia Calderone⁴, Eric Morand⁵ and Mandana Nikpour⁶, ¹Feinstein Institute for Medical Research, Mahasset, NY, ²Columbia University, College of Physicians & Surgeons, New York, NY, ³The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁴The University of Melbourne at St. Vincent’s Hospital, Melbourne, Australia, ⁵Monash University, Melbourne, Australia, ⁶The University of Melbourne, Melbourne, Australia, Melbourne, Australia
Background/Purpose: The Physician Global Assessment (PGA) is a frequently-used outcome measure in Systemic Lupus Erythematosus (SLE). The PGA is intended to encapsulate the physician’s judgement…
Abstract Number: 1678 • 2018 ACR/ARHP Annual Meeting
How Consistently Do Publications Define SLE? a Systematic Review
Linjia Jia¹, Ecem Sevim², Medha Barbhaiya² and Michael Lockshin³, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Barbara Volcker Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is clinically heterogeneous. ACR and/or SLICC classification criteria provide homogeneous populations for research purposes, but studies differ in selection and…
Abstract Number: 1695 • 2018 ACR/ARHP Annual Meeting
Differences between Early and Adult-Onset Systemic Lupus Erythematosus in Cohort of Argentinian Patients
Rodrigo Aguila Maldonado¹, Dora Pereira², Gisela Pendon³, Alberto Spindler⁴, Cecilia N. Pisoni⁵, Julio Hofman⁶, María Victoria Collado⁷, Judith Sarano⁸, Cesar Graf⁹, Graciela N Gómez¹⁰, Paula Alba¹¹, Claudia Elizabeth Pena¹, Ana Carolina Costi¹², Adrian Salas¹³, Ana Curti¹⁴, Oscar Rillo¹⁵, Silvia Beatriz Papasidero¹⁶, Veronica Bellomio¹⁷, Susana Roverano¹⁸, Marcela Schmid¹⁹, Alberto Allievi²⁰, Sebastián Muñoz²⁰, Walter J. Spindler²¹, Andrea Gonzalez²², Ana María Beron²³, Rosana Quintana²⁴, Agustina Damico²⁵, Andrea Gómez²⁶, Sergio Tolosa²⁷, Enrique Soriano²⁸, Alicia Eimon²⁹, Marta Silvia Espósito⁶, Leila Romina Ferreyra Mufarregue³⁰, Juan Pablo Ruffino³⁰, Verónica Saurit³¹, Edson Hernán Chiganer³⁰, Fabian Risueño³², Flavia Caputo³³, Edson Velozo³⁴, Juan Soldano³⁵, Monica Diaz³⁶ and Mercedes Garcia¹, ¹Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ²Rheumatology Section, Hospital Dr. Ricardo Gutiérrez, Argentina, Buenos Aires, Argentina, ³H Gutiérrez de La Plata, La Plata, Argentina, ⁴Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ⁵Internal Medicine, CEMIC, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina, ⁶Consultorio Privado, Buenos Aires, Argentina, ⁷Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁸Instituto Lanari, Buenos Aires, Argentina, ⁹Centro Médico Mitre, Paraná, Argentina, ¹⁰Diaz Colodrero 2537 8° A, Instituto de Investigaciones Medicas Alfredo Lanari, Capital Federal, Argentina, ¹¹Universidad Nacional de Cordoba, Rheumatology Unit Cordoba and Materno Neonatal Hospital, Córdoba, Argentina, ¹²Rheumatology Section, HIGA General San Martin La Plata, La Plata, Argentina, ¹³Rheumatology, HIGA General San Martin, La Plata, Argentina, ¹⁴Htal Lagomaggiori, Mendoza, Argentina, ¹⁵Hospital General de Agudos Dr Ignacio Pirovano, Argentina, Buenos Aires, Argentina, ¹⁶Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, ¹⁷Hospital Padilla, San Miguel de Tucumán, Argentina, ¹⁸Hospital José Maria Cullen, Santa Fe, Argentina, ¹⁹Hospital Jose María Cullen, Santa Fe, Argentina, ²⁰SAR, Buenos Aires, Argentina, ²¹Centro Médico Privado de Reumatología, Tucuman, Argentina, ²²Hospital Eva Perón, San Martín, Argentina, ²³Hospital de Clínicas, Buenos Aires, Argentina, ²⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, ²⁵Hospital Británico, Buenos Aires, Argentina, ²⁶Hospital Británico de Buenos Aires, CABA, Argentina, ²⁷Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ²⁸Hospital Italiano, Buenos Aires, Argentina, ²⁹CEMIC, Buenos Aires, Argentina, ³⁰Hospital Durand, Buenos Aires, Argentina, ³¹Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ³²Itemédica, Bahia Blanca, Argentina, ³³Hospital Posadas, Buenos Aires, Argentina, ³⁴Sanatorio Adventista del Plata, Entre Ríos, Ecuador, ³⁵Hospital Provincial, Rosario, Argentina, ³⁶SAR, Bariloche, Argentina
Background/Purpose: Approximately 20% of patients with Systemic Lupus Erythematosus (SLE) begin their illness in childhood or adolescence. These patients are described with a phenotype of…
Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Pratyaksha Sankhyan¹, Boonphiphop Boonpheng² and Christopher Cook², ¹Internal Medicine, East Tennessee State University, Johnson city, TN, ²Internal Medicine, East Tennessee State University, johnson city, TN
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.